Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by Mbxwatcheron Mar 08, 2022 1:05pm
144 Views
Post# 34496047

RE:RE:A bad year for MBX...at least so far

RE:RE:A bad year for MBX...at least so farOk, I still have not sold a single share but.............
Did you expect a stock price of .49.

I still think there a few things combining to make this happen.
1) world events aren't anybody's friend at the moment.  Risk stocks get hit the hardest.
2) I still believe this is seen as a Covid stock....they have to prove they are not. Saying it over and over does not appear to be enough....Only a few successful non-covid deals (HPV QAPS's), more VTM customers outside Ontario will send that message.
3) I am still stuck on the words:  " It will be a photo finish whether we get a Kinlytic deal by the end of 2021"    I think the explanation for the lack of a deal is poor.  I do not think anything else Cameron has done at MBX is poor, but they get an "F" from me on this one topic. I watched the MBX for beginners video with Adelaide Capital, and unless I missed it Kinlytic was not even mentioned by name.
4) I would like to know what happened to KRC Insights.  Where is the updated analysis.  I cant get over the feeling that we dont have it because they didnt like it.  Maybe I am wrong.

I think this stock does have the potential to tank.  I did not think that earlier.  We are dependent on the automation coming on line, and sales delivering the contracts that have been hinted at.
Until then we are in limbo, and the uncertainties are reflected in the stock price. IMO


<< Previous
Bullboard Posts
Next >>